OSR Health Inc (OSRH) Stock AnalysisOSRHStock AnalysisOSR Health Inc

OSR Health, Inc., formerly OSR Holdings, Inc., is a healthcare holding company. Its platforms include immuno-oncology, regenerative biologics, noninvasive glucose monitoring and medical device technologies. Its subsidiaries include VAXIMM AG (Vaximm); RMC Co., Ltd. (RMC); Darnatein Co., Ltd. (Darnatein), and Woori IO Co., Ltd. (Woori IO). Its VXM01 is a clinical stage VEGFR-2 inhibitor with pre-clinically proven anti-angiogenic activity and encouraging Phase 1/2 safety profile in pancreatic cancer and GBM. Its Darnatein platform is a synthetic biology platform employing AI to generate hybrid versions of endogenous proteins. Lead asset DRT-101 is engineered to function as a BMP super-agonist for joint cartilage regeneration, targeting OA with huge unmet medical needs and potential as a DMOAD. RMC is engaged in medical device distribution business that is also evolving into fourth-party logistics (4PL), offering bundled import licensing, regulatory, and logistics services.

OSR Holdings Inc is not a good buy right now due to significant financial instability and compliance risks. The current price is $0.28, which is below the Nasdaq compliance requirement of $1, and the company has a negative net income of -$848,905 in Q2 2026. Additionally, the stock has dropped 53% year-to-date and 72.57% over the past year, indicating a severe downtrend. The main risk is the potential delisting from Nasdaq, which could further erode investor confidence and market value.